Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Puma Biotechnology (PBYI) Gross Margin (2017 - 2025)

Puma Biotechnology's Gross Margin history spans 9 years, with the latest figure at 69.35% for Q4 2025.

  • For Q4 2025, Gross Margin fell 709.0% year-over-year to 69.35%; the TTM value through Dec 2025 reached 74.53%, up 248.0%, while the annual FY2025 figure was 74.53%, 248.0% up from the prior year.
  • Gross Margin reached 69.35% in Q4 2025 per PBYI's latest filing, down from 77.65% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 80.79% in Q4 2022 to a low of 63.87% in Q3 2024.
  • Average Gross Margin over 5 years is 75.18%, with a median of 76.49% recorded in 2024.
  • Peak YoY movement for Gross Margin: crashed -1449bps in 2023, then surged 1378bps in 2025.
  • A 5-year view of Gross Margin shows it stood at 78.51% in 2021, then increased by 3bps to 80.79% in 2022, then fell by -18bps to 66.3% in 2023, then rose by 15bps to 76.44% in 2024, then decreased by -9bps to 69.35% in 2025.
  • Per Business Quant, the three most recent readings for PBYI's Gross Margin are 69.35% (Q4 2025), 77.65% (Q3 2025), and 76.54% (Q2 2025).